MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
Organization & Developments: Sarepta
Parents
Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
Children
2018: Sarepta all-in on gene therapy pipeline, adding 3 CNS treatments in $30M Lacerta deal – Endpoints News
2018: Sarepta Obtains Impressive Early Data From DMD Gene Therapy Study_seekingalpha.com
2018: Sarepta Therapeutics: Continued Upside In 2018 - Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
2018: Sarepta Won't Let One Stumble Bring It Down - Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
2018: Sarepta: Riskier Than The Market Thinks_seekingalpha.com
2019: FDA surprises Sarepta by spurning its 2nd Duchenne drug
2019: Sarepta Stock Pops After FDA Places Rival's Gene Therapy On A Clinical Hold
2019: Sarepta was stunned by the rejection of Vyondys 53. Now it’s stunning everyone with a surprise accelerated approval – Endpoints News
2019: This Biotech Is More Than Its Lead Gene Therapies: Here Are 4 Drugs To Note_www.investors.com
2019: What's Wrong With Sarepta Therapeutics?_seekingalpha.com
2020: Stock Doctor: Selecta Biosciences Continues To Attract Partners As Sarepta Therapeutics Signs On For Gene Therapy
2020: FDA’s golodirsen CRL: Sarepta’s Duchenne drugs are dangerous to patients, offering only a small benefit. And where’s that confirmatory trial? – Endpoints News
2020: Sarepta: Leading The Genomic Medicine Pack
2021: Sarepta: Revenue Keeps Rising While We Wait For Functional Data
2021: UPDATED: Sarepta gene therapy for Duchenne muscular dystrophy fails on function
2022: Sarepta Therapeutics Up For Earnings Revenue Surprise_ seekingalpha.com
2023: Sarepta Stock Tanks As DMD Gene Therapy Fails Confirmatory Study
2023: Sarepta Therapeutics: A Virtual Monopoly In Duchenne Muscular Dystrophy_ seekingalpha
2023: Secondary Outcomes Hold Regulatory Promise (NASDAQ:SRPT)
2023: Updated: FDA approves Sarepta’s Duchenne muscular dystrophy gene therapy via accelerated pathway
2024: Arrowhead: The Sarepta Partnership Validates RNAi Platform And Reduces Risk
2024: Ruling in REGENXBIO-Sarepta Patent Case Threatens Gene Therapy Market
2024: Sarepta Halts Development of Next-Gen DMD Drug, Reports Robust Elevidys Sales
2024: Sarepta Jumps on Broad Approval for Muscular Dystrophy Drug
2024: Sarepta rebuilds drug pipeline with Arrowhead deal
2024: Sarepta Therapeutics Elevidys: the 200 Best Inventions of 2024
2024: Sarepta Therapeutics Muscles Up In DMD Rac
2024: Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts
2024: Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step
2024: Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
2024: Sarepta Therapeutics: Leading The Way In DMD Treatment With Gene Therapy Innovations
2024: Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval_seekingalpha.com
2024: Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
2024: Sparked by FDA expansion, Sarepta's Elevidys takes another leap in sales
2024: The Play On Sarepta Therapeutics_seekingalpha.com
2025: Patient dies in Sarepta gene therapy trial, adding to safety concerns
2025: Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning
2025: Sarepta reports 1 death after patient received DMD gene therapy Elevidys
2025: Sarepta Therapeutics crisis is huge blow to Duchenne families, company
2025: Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move
2025: Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
2025: Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness
2025: Sarepta Therapeutics’ SWOT analysis: strong Elevidys sales offset safety concerns
2025: Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks
2025: Sarepta will stop shipping Elevidys, Duchenne gene therapy
2025: Sarepta: A Dizzying Pivot From Gene Therapy Peril To An RNA Future (Rating Downgrade)
2025: Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
2025: Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating
2025: Second patient dies after getting Sarepta's Duchenne gene therapy
2025: Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades
Organization & Developments: Sarepta (Archives 2016-2017)
Jumps
*Key People: Sarepta
Finance & Acquisitions: Sarepta